Bacterial Disease
21 cases on antibiotic selection, dosing, and duration across bacteremia, endocarditis, osteoarticular and skin/soft-tissue infection, tuberculosis, and sexually transmitted bacterial disease — choose a case below to open its full multi-voice debate.
A pyelonephritis-source bacteremia is clearing fast on antibiotics. The disagreement isn’t about whether she’s responding — it’s about whether a stone still sitting in her ureter means the seven-day evidence doesn’t actually apply to her yet.
Two patients, the same organism, the same drug class under debate — one healthy and source-controlled, one neutropenic with nowhere for a surgeon to intervene. The question is whether a second antipseudomonal agent is ever the right default, and for whom.
Five days of correctly dosed vancomycin haven’t cleared his bacteremia. The next drug is not a simple swap — the same resistance mechanism that likely explains the failure may already be working against the drug meant to replace it.
A recovering kidney can’t be dosed around by a single trough level. The disagreement is whether the better method is worth adopting mid-admission, or whether the current tool, used more carefully, gets close enough.
A third C. diff recurrence in eight months. The real gap in her history isn’t how many times she’s relapsed — it’s that the guideline-preferred antibiotic for recurrence was never actually tried.
The one agent aimed directly at his toxin burden left the US market in 2025. What is left has to be chosen against a heart that has only recently stopped decompensating.
Surgical source control is already underway. What’s still contested is which antitoxin adjunct actually works on an organism that may already be resistant to the one with the longer track record.
Unreliable follow-up threatens both the line and the pill bottle. The real disagreement isn’t IV versus oral — it’s which failure mode is more survivable for a patient whose actual barrier is neither.
A prosthetic knee infection sits right at the edge of the window that would make implant retention straightforward. Imaging can’t settle it — only the surgeon’s own eyes, once the joint is open, can.
A childhood allergy label, never tested, may be keeping a bacteremic patient on the inferior second-line drug. The fix costs almost nothing if it happens today.
The shorter tuberculosis regimen he’s far more likely to finish shares a metabolic pathway with the drug protecting his transplanted kidney. Neither risk is hypothetical.
The regimen most likely to cure her tuberculosis efficiently includes two drugs that independently prolong a heart rhythm interval already running long before either one starts.
She is deteriorating despite everything given so far. The antibody therapy that might help was never proven to, because the trial built to answer the question stopped before it could.
A likely gonorrhea diagnosis, current guidance favoring a single drug, and a partner whose status is genuinely unknown rather than reassuringly clear. The gap is testable, not just arguable.
Penicillin is the only proven way to protect her pregnancy from this infection. Her allergy history is real enough that how carefully the team proceeds matters as much as how fast.
Every hour without antibiotics raises his risk in septic shock. Every antibiotic given before better source identification may cost information that changes his definitive care. His own numbers, not the general debate, decide it.
Her Lyme disease was treated correctly eight months ago. Her symptoms are real and unresolved anyway — and more antibiotics, the trials say plainly, won’t fix what’s actually still wrong.
A mass suspected to be cancer turns out to be a treatable infection. What remains genuinely contested is how aggressively to start, given an immune system that has been suppressed for fifteen years.
Neither of the usual ways to finish his antibiotic course is safe for him the way it would be for most patients. The evidence for the alternative is thinner — but so is his real chance of completing either standard option.
He is asking for a pill that would meaningfully lower his own infection risk. The same evidence shows it may come at a cost to people he will never meet.
Every criterion in the trials that changed this practice is met right here, in this patient, on this visit. Whether that’s enough to actually withhold a familiar prescription is the real test of an evidence-based policy.